We identified pathogenic and likely pathogenic variants and novel variants in cancer-associated genes (e.g., TP53, BRCA1, MDC1) and variants in other potential genes of interest (e.g., NBPF12, PLIN4, FGFR2). This evidence concerns the gene FGFR2 and cancer.